SimcoDerm Medical and Surgical Dermatology Center

Summary

SimcoDerm Medical and Surgical Dermatology Center is a medical facility located in BARRIE, Ontario. This center is recognized for care of Atopic Dermatitis, Psoriasis, Vitiligo, Skin Conditions, Plaque Psoriasis and other specialties. SimcoDerm Medical and Surgical Dermatology Center is involved with conducting 42 clinical trials across 34 conditions. There are 1 research doctors associated with this hospital, such as Maryam Shayesteh Alam.

Top PIs

Clinical Trials running at SimcoDerm Medical and Surgical Dermatology Center

Alopecia Areata

Psoriasis

Plaque Psoriasis

Prurigo Nodularis

Hidradenitis Suppurativa

Vitiligo

Eczema

Anastomotic Ulcer

Congenital Hair Disorder

Periprosthetic Bone Loss

Ritlecitinib

for Alopecia Areata

The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata. Alopecia areata is a disease that causes hair loss on the scalp, face, and areas of the body. Ritlecitinib is approved in many countries at a dose of 50 mg (milligram) taken by mouth once a day for the treatment of patients 12 years and older with severe alopecia areata. This study will look at both the 50 mg dose and a 100 mg dose. This study is seeking participants who: * Are 12 years of age or older * Have a diagnosis of alopecia areata * Have lost 50% or more of the hair on their scalp * Do not have any other conditions that causes hair loss * Are willing to stop all other treatments that they may be taking for alopecia areata About 550 participants will take part in in this study. Participants will be chosen by chance, like drawing names out of a hat, to receive 1 of 2 different amounts of ritlecitinib (50 mg and 100 mg) taken by mouth once daily. The 2 doses of ritlecitinib in this study will be compared to each other and also to data from previous studies. This will help to see if the 100 mg dose of ritlecitinib is safe and effective. People will be in this study for about 13 months. During the study, participants will need to visit the study site up to 9 times. Participants will undergo various tests and procedures such as: * alopecia areata assessment, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG (electrocardiogram), * photographs of the scalp and eyes. Participants will also be asked to complete questionnaires about their alopecia areata.

Recruiting

1 award

Phase 3

2 criteria

Upadacitinib

for Severe Alopecia Areata

This trial is testing upadacitinib, a medication that may help people with severe hair loss due to alopecia areata. The drug works by stopping the immune system from attacking hair roots. Adolescents and adults with severe alopecia areata are participating to see if this treatment is safe and effective.

Recruiting

1 award

Phase 3

6 criteria

Disease Burden Assessment

for Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.

Recruiting

1 award

N/A

2 criteria